LGVN
MaterialsLongeveron Inc - Class A
Live · NASDAQ · May 9, Close
What's Moving LGVN Today?
No stock-specific AI insight has been generated for LGVN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
LGVN News
21 articles- Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)Yahoo Finance·May 8, 2026
- Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026Yahoo Finance·May 5, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsBenzinga·Apr 10, 2026
- Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)Yahoo Finance·Apr 8, 2026
- Longeveron (LGVN) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 18, 2026
- Longeveron Inc. Q4 2025 Earnings Call SummaryMoby·Mar 18, 2026
- 2026 A Critical Pivot Point for LGVNYahoo Finance·Mar 18, 2026
- Longeveron Announces 2025 Full Year Financial Results and Provides Business UpdateYahoo Finance·Mar 17, 2026
- Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 ResultsYahoo Finance·Mar 16, 2026
- Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026Yahoo Finance·Mar 12, 2026
- Longeveron Announces Closing of Private Placement of up to $30 MillionYahoo Finance·Mar 11, 2026
- A $30 Million Reason to Buy Penny Stock Longeveron TodayBarchart·Mar 11, 2026
- BC-Most Active StocksYahoo Finance·Mar 10, 2026
- Longeveron Announces Private Placement of up to $30 MillionYahoo Finance·Mar 10, 2026
- LGVN Secures Operations Through Crucial TestYahoo Finance·Mar 10, 2026
- Trial Results from LGVN Continue to ImpressYahoo Finance·Feb 26, 2026
- Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem CellYahoo Finance·Feb 25, 2026
- LGVN Announces New CEO and Cost CutsYahoo Finance·Feb 17, 2026
- Longeveron® Appoints Stephen H. Willard as Chief Executive OfficerYahoo Finance·Feb 13, 2026
- Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher ProgramYahoo Finance·Feb 5, 2026
- Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)Yahoo Finance·Jan 29, 2026
All 21 articles loaded
Price Data
Fundamentals
Trading
About Longeveron Inc - Class A
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.